Lacnotuzumab (MCS110) is a humanized monoclonal antibody targeting CSF-1, inhibiting the macrophage colony-stimulating factor pathway upstream components, used in retinal disease research.
Purity:
>95%
CAS Number:
[1831128-32-5]
Target:
c-Fms
* VAT and and shipping costs not included. Errors and price changes excepted